68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)(68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel)) - 药物靶点：CD206_在研适应症：非小细胞肺癌，动脉粥样硬化，心脏结节病_专利_临床

概要

基本信息

药物类型

抗体偶联核素、诊断用放射药物

别名-

靶点

CD206

作用机制

CD206抑制剂(巨噬细胞甘露糖受体-1抑制剂)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [5]

在研适应症

非小细胞肺癌动脉粥样硬化心脏结节病+ [8]

非在研适应症-

原研机构

Universitair Ziekenhuis Brussel

在研机构

Universitair Ziekenhuis Brussel

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

4

项与 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel) 相关的临床试验

NCT05933239 / Recruiting临床2期IIT

A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.

开始日期2023-03-30

申办/合作机构

Universitair Ziekenhuis Brussel

EUCTR2021-005575-40-BE / Not yet recruiting临床2期IIT

A phase II study to evaluate the imaging potential of 68GaNOTA-Anti-MMR VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC).

开始日期2023-02-15

申办/合作机构-

NCT04758650 / Recruiting临床2期IIT

Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and sarcoïdosis

Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with oncological lesions in need of non-surgical therapy, patients with cardiovascular atherosclerosis, syndrome with abnormal immune activation and sarcoïdosis.

开始日期2021-01-26

申办/合作机构

Universitair Ziekenhuis Brussel

100 项与 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel) 相关的临床结果

登录后查看更多信息

100 项与 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel) 相关的转化医学

登录后查看更多信息

100 项与 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel) 相关的专利（医药）

登录后查看更多信息

100 项与 68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉粥样硬化	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
心脏结节病	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
颈动脉狭窄	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
头颈部肿瘤	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
霍奇金淋巴瘤	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
噬血细胞性淋巴组织细胞增多症	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
非霍奇金淋巴瘤	临床2期	比利时	Universitair Ziekenhuis Brussel	2021-01-26
乳腺癌	临床2期	比利时	Universitair Ziekenhuis Brussel	2019-11-05
恶性实体肿瘤	临床2期	比利时	Universitair Ziekenhuis Brussel	2019-11-05
皮肤黑色素瘤	临床2期	比利时	Universitair Ziekenhuis Brussel	2019-11-05